• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.CBF、Myb和Ets结合位点对于鼠逆转录病毒SL3-3的核心I元件在T淋巴细胞中的活性很重要。
J Virol. 1998 Apr;72(4):3129-37. doi: 10.1128/JVI.72.4.3129-3137.1998.
2
Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.CBF(AML1)对逆转录病毒增强子的转录激活需要第二个因子:与c-Myb协同作用的证据。
J Virol. 1996 Aug;70(8):5618-29. doi: 10.1128/JVI.70.8.5618-5629.1996.
3
Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.c-Myb结合位点对逆转录病毒SL3-3致淋巴瘤作用的重要性
J Virol. 1997 Feb;71(2):1213-9. doi: 10.1128/JVI.71.2.1213-1219.1997.
4
Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.核心结合因子α(AML1)和β亚基对鼠白血病病毒增强子核心的转录活性。
J Virol. 1995 May;69(5):2898-906. doi: 10.1128/JVI.69.5.2898-2906.1995.
5
Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.一种T细胞淋巴瘤逆转录病毒的核心结合因子(CBF/AML1)结合位点内的抑制突变。
J Virol. 1999 Mar;73(3):2143-52. doi: 10.1128/JVI.73.3.2143-2152.1999.
6
Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.淋巴瘤逆转录病毒CBF结合位点突变的回复突变体和抑制子的筛选。
J Virol. 1999 Sep;73(9):7599-606. doi: 10.1128/JVI.73.9.7599-7606.1999.
7
Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.减毒SL3-3小鼠白血病病毒突变体诱导的T淋巴瘤中AML1(核心)位点增强子突变的稳定性
J Virol. 1997 Jul;71(7):5080-7. doi: 10.1128/JVI.71.7.5080-5087.1997.
8
Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.Cbf和Ets对莫洛尼鼠白血病病毒及T细胞受体β链增强子的反式激活需要两种蛋白质的完整结合位点。
J Virol. 1995 Aug;69(8):4941-9. doi: 10.1128/JVI.69.8.4941-4949.1995.
9
Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types.血清反应因子和ELK-1蛋白重叠结合位点之间的协同相互作用介导了灵长类巨细胞病毒主要立即早期启动子在单核细胞和T淋巴细胞类型中的基础增强和佛波酯反应性。
J Virol. 1996 Dec;70(12):8590-605. doi: 10.1128/JVI.70.12.8590-8605.1996.
10
Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.通过在体内进化出的第二位点增强子变体,AML1位点(核心)突变的SL3-3鼠白血病病毒的淋巴瘤致瘤性增加且疾病特异性得以恢复。
J Virol. 1997 Oct;71(10):7273-80. doi: 10.1128/JVI.71.10.7273-7280.1997.

引用本文的文献

1
Lessons Learned from Mouse Mammary Tumor Virus in Animal Models.从动物模型中的小鼠乳腺肿瘤病毒中吸取的经验教训。
ILAR J. 2016;57(1):12-23. doi: 10.1093/ilar/ilv044.
2
Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.鼠 T 细胞淋巴母细胞淋巴瘤的基因表达谱分析鉴定出 S 期起始基因的失调。
Leuk Res. 2013 Oct;37(10):1383-90. doi: 10.1016/j.leukres.2013.04.012. Epub 2013 Jul 26.
3
Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.通过E-box基序而非重叠的糖皮质激素反应元件来控制致T淋巴瘤γ逆转录病毒的致病性和疾病特异性。
J Virol. 2009 Jan;83(1):336-46. doi: 10.1128/JVI.01368-08. Epub 2008 Oct 22.
4
ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.ALY是B型致白血病病毒增强子上RUNX1和c-Myb的常见共激活因子。
J Virol. 2007 Apr;81(7):3503-13. doi: 10.1128/JVI.02253-06. Epub 2007 Jan 17.
5
Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity.受体使用、Fli1激活以及小鼠品系对10A1鼠白血病病毒致白血病性的干细胞特异性的重要性。
J Virol. 2007 Jan;81(2):732-42. doi: 10.1128/JVI.01430-06. Epub 2006 Nov 1.
6
Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.致T淋巴细胞性SL3-3鼠白血病病毒增强子中所有Runx(AML1/核心)位点的突变揭示了诱导髓系白血病的巨大潜力,并有利于增强子向诱导其他疾病模式的方向进化。
J Virol. 2004 Dec;78(23):13216-31. doi: 10.1128/JVI.78.23.13216-13231.2004.
7
Duplication of U3 sequences in the long terminal repeat of mink cell focus-inducing viruses generates redundancies of transcription factor binding sites important for the induction of thymomas.水貂细胞融合诱导病毒长末端重复序列中U3序列的重复产生了对胸腺瘤诱导至关重要的转录因子结合位点冗余。
J Virol. 2003 Mar;77(5):3326-33. doi: 10.1128/jvi.77.5.3326-3333.2003.
8
Selection for c-myc integration sites in polyclonal T-cell lymphomas.多克隆T细胞淋巴瘤中c-myc整合位点的选择
J Virol. 2002 Mar;76(5):2087-99. doi: 10.1128/jvi.76.5.2087-2099.2002.
9
In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity.造血细胞中逆转录病毒增强子突变的体内分析:SP1/EGR1和ETS/GATA基序对长末端重复序列特异性有贡献。
J Virol. 2002 Jan;76(1):303-12. doi: 10.1128/jvi.76.1.303-312.2002.
10
Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1.B型白血病病毒具有一个与AML-1结合的T细胞特异性增强子。
J Virol. 2001 Mar;75(5):2174-84. doi: 10.1128/JVI.75.5.2174-2184.2001.

本文引用的文献

1
The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.猫白血病病毒长末端重复序列包含T细胞淋巴瘤致瘤性的一个强效遗传决定因素。
J Virol. 1997 Dec;71(12):9786-91. doi: 10.1128/JVI.71.12.9786-9791.1997.
2
ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function.ALY是LEF-1和AML-1的一种依赖于上下文的共激活因子,是TCRα增强子功能所必需的。
Genes Dev. 1997 Mar 1;11(5):640-53. doi: 10.1101/gad.11.5.640.
3
Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.c-Myb结合位点对逆转录病毒SL3-3致淋巴瘤作用的重要性
J Virol. 1997 Feb;71(2):1213-9. doi: 10.1128/JVI.71.2.1213-1219.1997.
4
Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.SL3-3小鼠白血病病毒增强子突变体诱导的淋巴瘤中第二位点前病毒增强子改变:核因子1结合位点的负面影响
J Virol. 1997 Feb;71(2):1196-206. doi: 10.1128/JVI.71.2.1196-1206.1997.
5
E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation.E盒序列与碱性螺旋-环-螺旋蛋白介导的转录激活的上下文依赖性TAL1/SCL调节
J Biol Chem. 1996 Dec 6;271(49):31463-9. doi: 10.1074/jbc.271.49.31463.
6
Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.CBF(AML1)对逆转录病毒增强子的转录激活需要第二个因子:与c-Myb协同作用的证据。
J Virol. 1996 Aug;70(8):5618-29. doi: 10.1128/JVI.70.8.5618-5629.1996.
7
Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines.在淋巴样细胞系中,碱性螺旋-环-螺旋蛋白介导的鼠白血病病毒转录的多种调控模式。
J Virol. 1996 Sep;70(9):5893-901. doi: 10.1128/JVI.70.9.5893-5901.1996.
8
Regulation of immature myeloid cell differentiation by PEBP2/CBF, Myb, C/EBP and Ets family members.PEBP2/CBF、Myb、C/EBP和Ets家族成员对未成熟髓样细胞分化的调控
Curr Top Microbiol Immunol. 1996;211:149-57. doi: 10.1007/978-3-642-85232-9_15.
9
The role of viral enhancer "core" motif-related sequences in regulating T cell receptor-gamma and -delta gene expression.病毒增强子“核心”基序相关序列在调节T细胞受体γ和δ基因表达中的作用。
J Immunol. 1993 May 1;150(9):3905-16.
10
Characterization of a protein that binds multiple sequences in mammalian type C retrovirus enhancers.一种结合哺乳动物C型逆转录病毒增强子中多个序列的蛋白质的特性分析。
J Virol. 1993 Apr;67(4):1976-86. doi: 10.1128/JVI.67.4.1976-1986.1993.

CBF、Myb和Ets结合位点对于鼠逆转录病毒SL3-3的核心I元件在T淋巴细胞中的活性很重要。

CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.

作者信息

Zaiman A L, Nieves A, Lenz J

机构信息

Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

出版信息

J Virol. 1998 Apr;72(4):3129-37. doi: 10.1128/JVI.72.4.3129-3137.1998.

DOI:10.1128/JVI.72.4.3129-3137.1998
PMID:9525638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC109765/
Abstract

Transcriptional enhancers within the long terminal repeats of murine leukemia viruses are major determinants of the pathogenic properties of these viruses. Mutations were introduced into the adjacent binding sites for three transcription factors within the enhancer of the T-cell-lymphomagenic virus SL3-3. The sites that were tested were, in 5'-to-3' order, a binding site for core binding factor (CBF) called core II, a binding site for c-Myb, a site that binds members of the Ets family of factors, and a second CBF binding site called core I. Mutation of each site individually reduced transcriptional activity in T lymphocytes. However, mutation of the Myb and core I binding sites had larger effects than mutation of the Ets or core II site. The relative effects on transcription in T cells paralleled the effects of the same mutations on viral lymphomagenicity, consistent with the idea that the role of these sequences in viral lymphomagenicity is indeed to regulate transcription in T cells. Mutations were also introduced simultaneously into multiple sites in the SL3-3 enhancer. The inhibitory effects of these mutations indicated that the transcription factor in T cells that recognizes the core I element of SL3-3, presumably CBF, needed to synergize with one or more factors bound at the upstream sites to function. This was tested further by generating a multimer construct that contained five tandem core I elements linked to a basal long terminal repeat promoter. This construct was inactive in T cells. However, transcriptional activity was detected with a multimer construct in which the transcription factor binding sites upstream of the core were also present. These results are consistent with the hypothesis that CBF requires heterologous transcription factors bound at nearby sites to function in T cells.

摘要

鼠白血病病毒长末端重复序列中的转录增强子是这些病毒致病特性的主要决定因素。将突变引入T细胞淋巴瘤病毒SL3-3增强子内三个转录因子的相邻结合位点。按5'至3'顺序测试的位点分别是:一个称为核心II的核心结合因子(CBF)结合位点、一个c-Myb结合位点、一个结合Ets家族因子成员的位点以及另一个称为核心I的CBF结合位点。单独突变每个位点都会降低T淋巴细胞中的转录活性。然而,Myb和核心I结合位点的突变比Ets或核心II位点的突变影响更大。对T细胞转录的相对影响与相同突变对病毒淋巴瘤致瘤性的影响平行,这与这些序列在病毒淋巴瘤致瘤性中的作用确实是调节T细胞转录的观点一致。还将突变同时引入SL3-3增强子的多个位点。这些突变的抑制作用表明,T细胞中识别SL3-3核心I元件的转录因子(可能是CBF)需要与一个或多个结合在上游位点的因子协同作用才能发挥功能。通过构建一个多聚体构建体进一步对此进行了测试,该构建体包含与基础长末端重复启动子相连的五个串联核心I元件。该构建体在T细胞中无活性。然而,在一个多聚体构建体中检测到了转录活性,该构建体中核心上游的转录因子结合位点也存在。这些结果与CBF需要与结合在附近位点的异源转录因子协同作用才能在T细胞中发挥功能的假设一致。